

# Severe eosinophilic asthma treated with mepolizumab : thresholds: a secondary analysis of the DREAM and ME

Lancet Respiratory Medicine, the  
4, 549-556

DOI: [10.1016/s2213-2600\(16\)30031-5](https://doi.org/10.1016/s2213-2600(16)30031-5)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Severe eosinophilic asthma and mepolizumab. <i>Lancet Respiratory Medicine</i> , 2016, 4, 528-529.	5.2	2
3	Benralizumab, an anti-interleukin-5 receptor $\hat{I}\pm$ monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2128-2141.	6.3	1,070
4	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting $\hat{I}^2$ -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2115-2127.	6.3	1,050
5	Anti-IL-5 for Severe Asthma. <i>Chest</i> , 2016, 150, 766-768.	0.4	13
6	Are emerging PGD2 antagonists a promising therapy class for treating asthma?. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 359-364.	1.0	20
7	Precision medicine in idiopathic pulmonary fibrosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 585-587.	0.2	15
8	Measuring Eosinophils to Make Treatment Decisions in Asthma. <i>Chest</i> , 2016, 150, 485-487.	0.4	22
10	Severe Asthma: Challenges and Precision Approaches to Therapy. <i>Pulmonary Therapy</i> , 2016, 2, 139-152.	1.1	1
11	Mepolizumab: A Review in Eosinophilic Asthma. <i>BioDrugs</i> , 2016, 30, 361-370.	2.2	16
12	Clinical trial research in focus: do trials prepare us to deliver precision medicine in those with severe asthma?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 92-95.	5.2	4
13	Can biomarkers help us hit targets in difficult-to-treat asthma?. <i>Respirology</i> , 2017, 22, 430-442.	1.3	36
14	A Deep Dive into Asthma Transcriptomics. Lessons from U-BIOPRED. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1279-1280.	2.5	9
15	Precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 254-260.	1.2	8
16	Severe eosinophilic asthma: a roadmap to consensus. <i>European Respiratory Journal</i> , 2017, 49, 1700634.	3.1	143
17	IgE and eosinophils as therapeutic targets in asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 42-49.	1.1	41
18	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 568-576.	5.2	99
19	T2-low asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 48-55.	1.2	75
20	Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook. <i>BioDrugs</i> , 2017, 31, 93-103.	2.2	20

#	ARTICLE	IF	CITATIONS
21	Biologics for asthma and allergy. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2017, 25, 231-234.	0.8	11
22	Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 390-400.	5.2	432
23	Mepolizumab, quality of life, and severe eosinophilic asthma. <i>Lancet Respiratory Medicine</i> , 2017, 5, 362-363.	5.2	5
24	Novel Biomarkers in Severe Asthma. <i>Archivos De Bronconeumologia</i> , 2017, 53, 175-176.	0.4	1
25	Nuevos biomarcadores del asma grave. <i>Archivos De Bronconeumologia</i> , 2017, 53, 175-176.	0.4	4
26	Eosinophilic Lung Disease. <i>American Journal of the Medical Sciences</i> , 2017, 354, 339-349.	0.4	27
27	Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1371-1377.e1.	2.0	17
28	Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. <i>Respiratory Medicine</i> , 2017, 123, 140-148.	1.3	46
29	Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 449-455.	1.3	5
30	Overlapping Effects of New Monoclonal Antibodies for Severe Asthma. <i>Drugs</i> , 2017, 77, 1769-1787.	4.9	32
31	Personalised medicine in asthma: time for action. <i>European Respiratory Review</i> , 2017, 26, 170064.	3.0	32
32	Emerging interleukin receptor antagonists for the treatment of asthma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 275-283.	1.0	1
33	Severe therapy resistant asthma in children: translational approaches to uncover sub-phenotypes. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 867-874.	1.0	14
34	Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 46, 88-98.	1.1	15
35	Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1613-1629.	13.9	397
36	Anti-IL5 therapies for asthma. <i>The Cochrane Library</i> , 2017, 9, CD010834.	1.5	198
37	Severe and Difficult-to-Treat Asthma in Adults. <i>New England Journal of Medicine</i> , 2017, 377, 965-976.	13.9	357
38	Response to omalizumab in patients with severe allergic asthma: A real-life study. <i>Respiratory Medicine</i> , 2017, 131, 109-113.	1.3	9

#	ARTICLE	IF	CITATIONS
39	Biomarkers for severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1509-1518.	1.5	180
40	Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1572-1581.e3.	2.0	116
41	Role of sputum biomarkers in the management of asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 34-40.	1.2	17
42	Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 918-927.	2.0	283
43	Point-of-care blood eosinophil count in a severe asthma clinic setting. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 16-20.	0.5	26
44	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 40-45.	1.0	27
45	Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. , 2017, 169, 57-77.		65
46	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 145-161.	2.4	14
47	Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma – an update. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 143-149.	1.3	27
48	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1167-1175.e2.	1.5	78
49	Biologics in the treatment of severe asthma. <i>Allergologia Et Immunopathologia</i> , 2017, 45, 45-49.	1.0	8
50	Recognition and management of severe asthma: A Canadian Thoracic Society position statement. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 199-221.	0.2	42
51	Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. <i>Biologics: Targets and Therapy</i> , 2017, Volume 11, 81-95.	3.0	22
52	Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma. <i>Frontiers in Medicine</i> , 2017, 4, 136.	1.2	31
53	An algorithmic approach for the treatment of severe uncontrolled asthma. <i>ERJ Open Research</i> , 2018, 4, 00125-2017.	1.1	58
54	Atopic dermatitis is an important comorbidity in severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 661-662.	0.5	9
55	Cytokine-targeting biologics for allergic diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 376-381.	0.5	38
56	Treating insect-bite hypersensitivity in horses with active vaccination against IL-5. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1194-1205.e3.	1.5	56

#	ARTICLE	IF	CITATIONS
57	Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1982-1988.e1.	2.0	24
58	Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 980-986.e1.	2.0	60
59	Biomarkers and asthma management: analysis and potential applications. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 96-108.	1.1	21
60	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 167-181.	21.5	294
61	Advances and Evolving Concepts in Allergic Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 064-081.	0.8	14
62	Rigor Is Needed When Making Comparative Analyses of Biologics in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1508-1510.	2.5	2
63	Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 874-882.e4.	2.0	19
64	Asthma. <i>Lancet, The</i> , 2018, 391, 783-800.	6.3	1,105
65	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 737-748.	1.3	129
66	Therapeutic antibodies: A new era in the treatment of respiratory diseases?. , 2018, 189, 149-172.		32
67	Biologics in pediatric lung disease. <i>Current Opinion in Pediatrics</i> , 2018, 30, 366-371.	1.0	2
68	Blood biomarkers in chronic airways diseases and their role in diagnosis and management. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 361-374.	1.0	10
69	Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 318-330.	2.9	7
70	Treatable traits of chronic airways disease. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 24-31.	1.2	24
71	Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. <i>Frontiers of Medicine</i> , 2018, 12, 340-349.	1.5	15
72	Eosinophils and eosinophil-associated diseases: An update. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 505-517.	1.5	71
73	Precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 4-10.	1.2	61
74	Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1216-1219.	2.5	71

#	ARTICLE	IF	CITATIONS
75	Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 490-497.	2.7	121
76	Eosinophilic and Noneosinophilic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 22-37.	2.5	248
77	Biologic agents for severe asthma patients: clinical perspectives and implications. <i>Internal and Emergency Medicine</i> , 2018, 13, 155-176.	1.0	13
78	Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Asthma</i> , 2018, 55, 956-965.	0.9	21
79	Blood eosinophils: The forgotten man of inhaled steroid dose titration. <i>Clinical and Experimental Allergy</i> , 2018, 48, 93-95.	1.4	17
80	Asthma: personalized and precision medicine. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 51-58.	1.1	57
81	Biologic and Emerging Therapies for Allergic Disease. , 2018, , 1-21.		0
82	Management of Severe Asthma in Children. <i>Current Treatment Options in Pediatrics</i> , 2018, 4, 438-455.	0.2	0
83	Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2151-2153.	2.0	12
84	Exacerbations of severe asthma in patients treated with mepolizumab. <i>European Respiratory Journal</i> , 2018, 52, 1801127.	3.1	16
85	Biomarkers in asthma: state of the art. <i>Asthma Research and Practice</i> , 2018, 4, 10.	1.2	78
86	Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis. <i>European Clinical Respiratory Journal</i> , 2018, 5, 1536097.	0.7	47
87	Severe refractory asthma: current treatment options and ongoing research. <i>Drugs in Context</i> , 2018, 7, 1-15.	1.0	22
88	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	42
89	Eosinophils Target Therapy for Severe Asthma: Critical Points. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	37
90	Recent developments and highlights in biomarkers in allergic diseases and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2290-2305.	2.7	77
91	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880849.	1.0	53
92	Health characteristics of patients with asthma, COPD and asthma&ndash;COPD overlap in the NHANES database. <i>International Journal of COPD</i> , 2018, Volume 13, 2859-2868.	0.9	27

#	ARTICLE	IF	CITATIONS
93	Omaliuzumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International, 2018, 2018, 1-10.	0.9	29
94	The Cell Research Trends of Asthma: A Stem Frequency Analysis of the Literature. Journal of Healthcare Engineering, 2018, 2018, 1-10.	1.1	1
95	Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. Expert Review of Respiratory Medicine, 2018, 12, 957-963.	1.0	10
96	Burden of disease associated with a COPD eosinophilic phenotype. International Journal of COPD, 2018, Volume 13, 2425-2433.	0.9	19
97	Biologics and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2018, 141, 1983-1991.	1.5	28
98	Role of Group 2 Innate Lymphocytes in Aspirin-exacerbated Respiratory Disease Pathogenesis. American Journal of Rhinology and Allergy, 2018, 32, 7-11.	1.0	31
99	Biological therapies for eosinophilic asthma. Expert Opinion on Biological Therapy, 2018, 18, 747-754.	1.4	38
100	Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. Advances in Therapy, 2018, 35, 1059-1068.	1.3	14
101	GLUCOLD, eosinophils and chronic obstructive pulmonary disease. Respiriology, 2018, 23, 966-967.	1.3	1
102	Asthma Endotyping and Biomarkers in Childhood Asthma. Pediatric, Allergy, Immunology, and Pulmonology, 2018, 31, 44-55.	0.3	123
103	Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion, 2018, 34, 2075-2088.	0.9	72
104	Optimising treatment for severe asthma. Medical Journal of Australia, 2018, 209, S22-S27.	0.8	20
105	Discovery and Validation of New Biomarkers for Personalizing Asthma Therapy. , 2018, , 87-95.		1
106	Predicting and Preventing Asthma Exacerbations. , 2018, , 129-141.		0
107	Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response. BMC Pulmonary Medicine, 2018, 18, 119.	0.8	96
108	Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS ONE, 2018, 13, e0201143.	1.1	28
109	Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. Frontiers in Medicine, 2018, 5, 49.	1.2	140
110	Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. Current Drug Targets, 2018, 19, 1882-1896.	1.0	60

#	ARTICLE	IF	CITATIONS
112	Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. <i>Allergy, Asthma and Clinical Immunology</i> , 2018, 14, 15.	0.9	16
113	Design and estimation in clinical trials with subpopulation selection. <i>Statistics in Medicine</i> , 2018, 37, 4335-4352.	0.8	18
114	Enfermedad respiratoria relacionada con aspirina tratada con mepolizumab en un paciente pediátrico. <i>Archivos De Bronconeumología</i> , 2019, 55, 55-57.	0.4	2
115	Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 165-174.e4.	2.0	30
116	Change in biomarkers of type-2 inflammation following severe exacerbations of asthma. <i>Thorax</i> , 2019, 74, 95-98.	2.7	16
117	Options of immunotherapeutic treatments for children with asthma. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 937-949.	1.0	6
118	The spectrum of therapeutic activity of mepolizumab. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 959-967.	1.3	10
119	Blood eosinophil count correlates with severity of respiratory failure in life-threatening asthma and predicts risk of subsequent exacerbations. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1578-1586.	1.4	16
120	No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia. <i>Respiratory Medicine</i> , 2019, 155, 26-28.	1.3	6
121	Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2689-2696.e2.	2.0	24
122	New and Emerging Therapies for Pediatric Atopic Dermatitis. <i>Paediatric Drugs</i> , 2019, 21, 239-260.	1.3	29
123	Exploring the Utility of Noninvasive Type 2 Inflammatory Markers for Prediction of Severe Asthma Exacerbations in Children and Adolescents. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2624-2633.e2.	2.0	21
124	Phenotypes and endotypes of adult asthma: Moving toward precision medicine. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1-12.	1.5	270
125	Reassessing the Role of Eosinophils as a Biomarker in Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 962.	1.0	18
126	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. <i>European Respiratory Journal</i> , 2019, 54, 1900900.	3.1	56
127	Acute Severe Asthma in Adolescent and Adult Patients: Current Perspectives on Assessment and Management. <i>Journal of Clinical Medicine</i> , 2019, 8, 1283.	1.0	30
128	Severe Eosinophilic Asthma. <i>Journal of Clinical Medicine</i> , 2019, 8, 1375.	1.0	73
129	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. <i>European Respiratory Journal</i> , 2019, 54, 1900108.	3.1	12



#	ARTICLE	IF	CITATIONS
130	An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. <i>Cell</i> , 2019, 179, 417-431.e19.	13.5	76
131	Obesity and adult asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 44-50.	1.2	8
132	Contribution of airway eosinophils in airway wall remodeling in asthma: Role of <i>MMP10</i> and <i>MET</i> . <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1102-1112.	2.7	32
133	Biologic and Emerging Therapies for Allergic Disease. , 2019, , 961-981.		0
134	Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers. <i>Pharmacological Research</i> , 2019, 146, 104296.	3.1	30
135	Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. <i>Respiratory Medicine</i> , 2019, 154, 69-75.	1.3	28
136	Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 617-630.	1.4	14
137	Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 37.	0.9	24
138	Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1379-1392.	2.0	47
139	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2293-2311.	2.7	76
140	Airway inflammation in COPD: progress to precision medicine. <i>European Respiratory Journal</i> , 2019, 54, 1900651.	3.1	163
141	An evaluation of mepolizumab for the treatment of severe asthma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 491-500.	1.4	5
142	The Cytokines of Asthma. <i>Immunity</i> , 2019, 50, 975-991.	6.6	622
143	Are biological drugs effective and safe in older severe asthmatics?. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 369-380.	1.0	11
144	Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of $\geq 300$ cells/ $\mu$ L. <i>Respiratory Medicine</i> , 2019, 151, 139-141.	1.3	9
145	Asthma progression and mortality: the role of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2019, 54, 1900491.	3.1	96
146	Selection of Biologics in Severe Asthma: A Multifaceted Algorithm. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 325-328.	0.6	5
147	Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 394.	1.1	53

#	ARTICLE	IF	CITATIONS
148	Eosinophils capture viruses, a capacity that is defective in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1898-1909.	2.7	79
149	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1430-1436.	2.0	3
150	Biologicals in the Treatment of Pediatric Atopic Diseases. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 131-151.	0.9	5
151	Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. <i>Respiratory Medicine</i> , 2019, 159, 105806.	1.3	43
152	Precision medicine in childhood asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 141-147.	1.1	13
153	Severe asthma in children: therapeutic considerations. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 132-140.	1.1	8
154	Biological treatments for severe asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 379-386.	1.1	21
155	Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 508-517.	2.5	68
156	Variability of blood eosinophils in patients in a clinic for severe asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 163-170.	1.4	28
157	Aspirin-Exacerbated Respiratory Disease in a Pediatric Patient Treated with Mepolizumab. <i>Archivos De Bronconeumologia</i> , 2019, 55, 55-57.	0.4	4
158	Role of Biologics in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 433-445.	2.5	296
159	Validation and Qualification of Biomarkers and Their Translation Into Pathway-Specific Diagnostic Tests. , 2019, , 95-101.		0
160	Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 190-200.e20.	1.5	175
161	Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading. <i>Journal of Asthma</i> , 2019, 56, 459-472.	0.9	7
162	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2020, 55, 1900588.	3.1	380
163	Towards Precision Medicine in Pediatric Severe Asthma: An Update on Current and Emerging Biomarkers. <i>Current Respiratory Medicine Reviews</i> , 2020, 15, 187-194.	0.1	0
164	Correlation between eosinophil count, its genetic background and body mass index: The Nagahama Study. <i>Allergology International</i> , 2020, 69, 46-52.	1.4	35
165	A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. <i>Clinical and Experimental Allergy</i> , 2020, 50, 189-197.	1.4	14

#	ARTICLE	IF	CITATIONS
166	Anti-IL5 and anti-IL5R $\alpha$ therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series. <i>European Respiratory Journal</i> , 2020, 55, 1901333.	3.1	42
167	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 370-380.	2.7	37
168	Anti-IL-4/IL-13 for the treatment of asthma: the story so far. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 283-294.	1.4	25
169	Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. <i>Respiratory Research</i> , 2020, 21, 3.	1.4	49
170	The use of biologic therapies for the management of pediatric asthma. <i>Pediatric Pulmonology</i> , 2020, 55, 803-808.	1.0	19
171	Secondary loss of response to mepolizumab in severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 736-738.	2.0	5
172	The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma. <i>Respiratory Medicine: X</i> , 2020, 2, 100010.	1.4	3
173	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1460-1463.	2.7	16
174	Characterization of Severe Asthma Worldwide. <i>Chest</i> , 2020, 157, 790-804.	0.4	165
175	Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 465-473.	2.0	54
176	New developments in asthma therapeutics. <i>Current Opinion in Pharmacology</i> , 2020, 51, 59-65.	1.7	3
177	Japanese guidelines for adult asthma 2020. <i>Allergology International</i> , 2020, 69, 519-548.	1.4	94
178	Biologics for the Treatments of Allergic Conditions. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 549-564.	0.7	9
179	Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. <i>World Allergy Organization Journal</i> , 2020, 13, 100462.	1.6	38
180	Pragmatic Clinical Perspective on Biologics for Severe Refractory Type 2 Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3363-3370.	2.0	32
181	Monoclonal antibodies for the treatment of severe asthma. <i>The Prescriber</i> , 2020, 31, 23-28.	0.1	3
182	Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report. <i>Breathe</i> , 2020, 16, 200058.	0.6	5
183	Biologic treatment options for severe asthma. <i>Current Opinion in Immunology</i> , 2020, 66, 151-160.	2.4	23

#	ARTICLE	IF	CITATIONS
184	Pharmacotherapeutic management of asthma in the elderly patient. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1991-2010.	0.9	4
185	Biologics in severe asthma: the overlap endotype - opportunities and challenges. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1427-1434.	1.4	16
186	&lt;p&gt;Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights&lt;/p&gt;. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 301-313.	1.5	15
187	Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000151.	3.1	84
188	Towards a personalised treatment approach for asthma attacks. <i>Thorax</i> , 2020, 75, 1119-1129.	2.7	13
189	New perspectives in bronchial asthma: pathological, immunological alterations, biological targets, and pharmacotherapy. <i>Immunopharmacology and Immunotoxicology</i> , 2020, 42, 521-544.	1.1	16
190	Risk factors associated with frequent exacerbations in asthma. <i>Respiratory Medicine: X</i> , 2020, 2, 100022.	1.4	2
192	Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 973-982.	2.5	105
193	Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2349-2356.	1.4	18
194	Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1237-1244.	1.4	13
195	Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 613-617.	0.9	14
196	Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680.	5.2	81
197	The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. <i>Allergology International</i> , 2020, 69, 178-186.	1.4	106
198	Real-world experience with mepolizumab: Does it deliver what it has promised?. <i>Clinical and Experimental Allergy</i> , 2020, 50, 687-695.	1.4	54
199	Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. <i>Drug Safety</i> , 2020, 43, 409-425.	1.4	47
200	Beyond type 2 cytokines in asthma - new insights from old clinical trials. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 463-475.	1.5	9
201	Mepolizumab effectiveness and identification of super-responders in severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1902420.	3.1	124
202	Blood eosinophils: In quest of a Holy Grail for personalized asthma treatment with biologics. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1294-1297.	2.7	4

#	ARTICLE	IF	CITATIONS
203	Phenotyping severe asthma: a rationale for biologic therapy. Expert Review of Precision Medicine and Drug Development, 2020, 5, 265-274.	0.4	6
204	Factors that affect blood eosinophil counts in a non-asthmatic population: Post hoc analysis of data from Brazil. World Allergy Organization Journal, 2020, 13, 100119.	1.6	11
205	How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?. Clinical and Experimental Allergy, 2020, 50, 994-1006.	1.4	11
206	Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092923.	1.0	38
207	Allergic Endotypes and Phenotypes of Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 429-440.	2.0	144
208	Inflammatory mechanisms linking maternal and childhood asthma. Journal of Leukocyte Biology, 2020, 108, 113-121.	1.5	30
209	Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab. Expert Review of Respiratory Medicine, 2020, 14, 353-365.	1.0	23
210	Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet, The, 2020, 395, 371-383.	6.3	102
211	Diagnosis and Management of T2-High Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 442-450.	2.0	51
212	Blood Eosinophilâ€‘directed Management of Airway Disease. The Past, Present, and Future. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 637-639.	2.5	10
213	Real-World Effectiveness and the Characteristics of a â€‘Super-Responderâ€‘to Mepolizumab in Severe Eosinophilic Asthma. Chest, 2020, 158, 491-500.	0.4	135
214	Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments. Frontiers in Medicine, 2020, 7, 98.	1.2	16
215	Targeted biologic therapy for asthma. British Medical Bulletin, 2020, 133, 16-35.	2.7	5
216	Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochemical Pharmacology, 2020, 179, 113978.	2.0	34
217	Perception of oral corticosteroids in adult patients with asthma in France. Journal of Asthma, 2021, 58, 946-957.	0.9	7
218	Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study. Turkish Journal of Medical Sciences, 2020, 44, 433-441.	0.4	18
219	Disease burden of eosinophilic airway disease: Comparing severe asthma, <scp>COPD</scp> and <scp>asthmaâ€‘COPD</scp> overlap. Respirology, 2021, 26, 52-61.	1.3	16
220	Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. Journal of Asthma, 2021, 58, 651-658.	0.9	26

#	ARTICLE	IF	CITATIONS
221	Longitudinal Outcomes of Severe Asthma: Real-World Evidence of Multidimensional Analyses. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1285-1294.e6.	2.0	13
222	Economic considerations on the usage of biologics in the allergy clinic. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 191-209.	2.7	8
223	Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1121-1132.e7.	2.0	19
224	Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma: An analysis from the Hokkaido Severe Asthma Cohort Study. <i>Allergology International</i> , 2021, 70, 68-73.	1.4	7
225	Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma—A Real-Life Evaluation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1194-1200.	2.0	102
226	Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1294-1297.	2.7	13
227	Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. <i>Thorax</i> , 2021, 76, 220-227.	2.7	83
228	Targeted therapy in eosinophilic chronic obstructive pulmonary disease. <i>ERJ Open Research</i> , 2021, 7, 00437-2020.	1.1	13
229	Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. <i>Asia Pacific Allergy</i> , 2021, 11, e31.	0.6	10
230	Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities. <i>Life Sciences</i> , 2021, 267, 118973.	2.0	16
231	A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	56
232	Modulating Th2 Cell Immunity for the Treatment of Asthma. <i>Frontiers in Immunology</i> , 2021, 12, 637948.	2.2	84
233	Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3340.	1.8	27
234	Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3969.	1.8	12
235	A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1978-1987.	1.5	19
236	Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2021, 384, 1800-1809.	13.9	435
237	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. <i>Respiratory Research</i> , 2021, 22, 144.	1.4	18
238	Treating severe asthma: Targeting the IL-5 pathway. <i>Clinical and Experimental Allergy</i> , 2021, 51, 992-1005.	1.4	30

#	ARTICLE	IF	CITATIONS
239	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. <i>Pulmonologiya</i> , 2021, 31, 272-295.	0.2	0
240	Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. <i>Respiratory Research</i> , 2021, 22, 184.	1.4	13
241	Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). <i>European Respiratory Journal</i> , 2022, 59, 2100396.	3.1	46
242	Novel therapeutic approaches targeting endotypes of severe airway disease. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1303-1316.	1.0	9
243	Exacerbation Rate Reduction with Mepolizumab, Stratified by Maintenance OCS Use and Eosinophil Levels. A Post-Hoc Analysis of DREAM and MENSA Studies. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 32, 0.	0.6	0
244	Pediatric problematic severe asthma: Recent advances in management. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1405-1415.	1.1	6
245	Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 675-683.	1.5	7
246	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. <i>International Journal of COPD</i> , 2021, Volume 16, 1755-1770.	0.9	30
247	ACO (Asthmaâ€œCOPD Overlap) Is Independent from COPD: The Case Against. <i>Diagnostics</i> , 2021, 11, 1189.	1.3	4
248	Comparing Patient Characteristics, Clinical Outcomes, and Biomarkers of Severe Asthma Patients in Taiwan. <i>Biomedicines</i> , 2021, 9, 764.	1.4	2
249	Impact of controlled high-sucrose and high-fat diets on eosinophil recruitment and cytokine content in allergen-challenged mice. <i>PLoS ONE</i> , 2021, 16, e0255997.	1.1	5
250	Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4353-4370.	2.0	12
251	Biological therapy for severe asthma. <i>Asthma Research and Practice</i> , 2021, 7, 12.	1.2	19
252	A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 702-712.	1.1	11
253	Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 790-798.	1.5	147
254	Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital. <i>World Allergy Organization Journal</i> , 2021, 14, 100547.	1.6	6
255	Factors leading to discontinuation of biologic therapy in patients with severe asthma. <i>Journal of Asthma</i> , 2022, 59, 1839-1849.	0.9	7
256	Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10150.	1.8	17



#	ARTICLE	IF	CITATIONS
257	Recent Insights into the Management of Inflammation in Asthma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4371-4397.	1.6	18
258	REal world Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. <i>Drugs</i> , 2021, 81, 1763-1774.	4.9	30
259	Treatment Response Biomarkers in Asthma and COPD. <i>Diagnostics</i> , 2021, 11, 1668.	1.3	5
260	From DREAM to REALITIÁ and beyond: Mepolizumab for the treatment of eosinophilÁ-driven diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 778-797.	2.7	25
261	Impact of Blood Eosinophil Variability in Asthma: A Real-Life Population Study. <i>Annals of the American Thoracic Society</i> , 2022, 19, 407-414.	1.5	11
262	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1141-1153.	5.2	263
263	Anti-Interleukin-5 in the Management of Eosinophilic Asthma: A Review of Effectiveness, Safety, and Budgetary Impact From the Perspective of the Brazilian Health System. <i>Value in Health Regional Issues</i> , 2021, 26, 169-181.	0.5	0
264	Mepolizumab para el tratamiento de asma grave eosinofÁlica. <i>Revista Alergia Mexico</i> , 0, 67, .	0.9	3
265	The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children. <i>Annals of Thoracic Medicine</i> , 2021, 16, 4.	0.7	34
266	The use of biologics for immune modulation in allergic disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 1452-1462.	3.9	44
267	Clinical biomarkers and noninvasive assessment of severe asthma. , 2019, , 93-112.		2
268	Biologics targeting type 2 inflammation in severe asthma. , 2019, , 285-303.		1
269	Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0166833.	1.1	51
270	Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype. <i>Pulmonologiya</i> , 2020, 30, 227-244.	0.2	11
271	A Low Serum CCL4/MIP-1Á <sup>2</sup> Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab. <i>Internal Medicine</i> , 2020, 59, 2849-2855.	0.3	8
272	The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children. <i>Annals of Thoracic Medicine</i> , 2019, 14, 3.	0.7	45
273	Future Risks in Patients With Severe Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 763.	1.1	43
274	Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	20



#	ARTICLE	IF	CITATIONS
275	Targeting eosinophils: severe asthma and beyond. <i>Drugs in Context</i> , 2019, 8, 212587.	1.0	20
276	Novel therapeutic targets for allergic airway disease in children. <i>Drugs in Context</i> , 2019, 8, 1-15.	1.0	11
277	The Type of Patients Requiring Aerosol Therapy (to Treat What and Where?). , 2021, , 1-25.		0
278	Using Fractional Exhaled Nitric Oxide Measurement in Clinical Asthma Management. <i>Chest</i> , 2022, 161, 906-917.	0.4	23
279	Biologics for Asthma and Allergic Skin Diseases in Children. <i>Pediatrics</i> , 2021, 148, .	1.0	3
280	Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors. <i>Biomedicines</i> , 2021, 9, 1497.	1.4	12
281	Molecular targeted therapies for asthma : current management and future directions. <i>Nihon Shoni Alerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology</i> , 2017, 31, 165-173.	0.0	0
282	Specific Therapies for Asthma Endotypes: A New Twist in Drug Development. <i>Birkhauser Advances in Infectious Diseases</i> , 2017, , 209-238.	0.3	0
283	VI. Evolution of Asthma Treatments. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 1043-1048.	0.0	0
284	A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma. <i>Cureus</i> , 2018, 10, e3216.	0.2	2
285	VIII. Tailor-made Therapy: Present and Future Treatment Options for Refractory Asthma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 2113-2120.	0.0	0
286	PROFILE OF BRONCHIAL INFLAMMATION AND CLINICAL FEATURES OF MILD BRONCHIAL ASTHMA. <i>Bulletin Physiology and Pathology of Respiration</i> , 2018, 1, 8-14.	0.0	4
287	Future Treatment and Other New Biologics for Asthma. <i>Respiratory Disease Series</i> , 2019, , 177-189.	0.1	0
288	THE COMPLEX CHARACTERISTIC OF EOSINOPHIL LEVEL OF INFLAMMATION IN PATIENTS WITH BRONCHIAL ASTHMA IN THE COLD-INDUCED BRONCHOSPASM. <i>Bulletin Physiology and Pathology of Respiration</i> , 2019, 1, 8-14.	0.0	1
289	Evaluation of difficult-to-treat and severe asthma in adults. , 2019, , 265-284.		2
290	A Possible Explanation for Non-responders, Responders and Super-responders to Biologics in Severe Asthma. <i>Exploratory Research and Hypothesis in Medicine</i> , 2019, X, 1-4.	0.1	0
291	A Possible Explanation for Non-responders, Responders and Super-responders to Biologics in Severe Asthma. <i>Exploratory Research and Hypothesis in Medicine</i> , 2019, X, 1-4.	0.1	1
292	Scope of the Problem, Definition, and Pathophysiology. <i>Respiratory Medicine</i> , 2020, , 1-23.	0.1	0

#	ARTICLE	IF	CITATIONS
293	Practical Considerations in the Management of Eosinophilic Asthma. <i>Respiratory Medicine</i> , 2020, , 181-206.	0.1	0
294	Severe Asthma in Childhood: Special Considerations. <i>Respiratory Medicine</i> , 2020, , 265-295.	0.1	0
295	Severe Asthma: Clinical Studies and Clinical Trials in Children. , 2020, , 271-285.		0
296	Confirming the Diagnosis of Severe Asthma in Children. , 2020, , 49-71.		2
297	Potential Therapeutic Options for Severe Asthma in Children: Lessons from Adult Trials. , 2020, , 287-312.		0
298	Successful management of severe bronchial asthma: the right choice of biologic therapy in properly selected patients. <i>Meditsinskiy Sovet</i> , 2019, , 22-28.	0.1	0
299	Precision medicine applications for severe asthma. <i>LymphoSign Journal</i> , 2019, 6, 117-135.	0.1	0
300	Diagnostic and treatment options for patients with COPD as part of real clinical practice. Approaches to the treatment of patients with various phenotypes according to GOLD (2019): materials of the Council of Experts of the Siberian Federal District, Chita and Buryatia, dated 03.15.19. <i>Pulmonologiya</i> , 2020, 30, 245-251.	0.2	0
303	Omalizumab and modification of bronchial asthma natural course. <i>Meditsinskiy Sovet</i> , 2021, , 17-25.	0.1	2
304	Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. <i>Biomedicines</i> , 2021, 9, 1550.	1.4	11
305	Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 422-432.	2.0	28
306	Eosinophilic Chronic Obstructive Pulmonary Disease. <i>Lung</i> , 2021, 199, 589-595.	1.4	7
307	Targeted therapy in bronchial asthma. Benralizumab: focus on patients using systemic glucocorticosteroids. <i>Meditsinskiy Sovet</i> , 2020, , 9-16.	0.1	4
308	The use of biologics in personalized asthma care. <i>Expert Review of Clinical Immunology</i> , 2021, , 1-9.	1.3	0
310	Are serum immunoglobulin concentrations a predictive biomarker of response to anti-IL5/IL5R $\pm$ therapies?. <i>Respiratory Medicine and Research</i> , 2022, 81, 100882.	0.4	0
311	Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. <i>ERJ Open Research</i> , 2022, 8, 00560-2021.	1.1	9
312	Current unmet needs and potential solutions to uncontrolled asthma. <i>European Respiratory Review</i> , 2022, 31, 210176.	3.0	24
313	Differential diagnosis of pulmonary eosinophilia. , 2022, , 19-36.		3

#	ARTICLE	IF	CITATIONS
314	Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 70.	1.1	2
315	Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologics in Severe Asthma. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 241-249.	1.6	5
316	Eosinophilia Is Associated with Improved COVID-19 Outcomes in Inhaled Corticosteroid-Treated Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 742-750.e14.	2.0	16
317	Biologics in Asthma: A Molecular Perspective to Precision Medicine. <i>Frontiers in Pharmacology</i> , 2021, 12, 793409.	1.6	28
318	When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma. <i>BMJ Case Reports</i> , 2022, 15, e244503.	0.2	1
319	Eosinophilic asthma. , 2022, , 73-99.		2
320	Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 410-419.	2.0	21
321	Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience. <i>Journal of Asthma</i> , 2023, 60, 158-166.	0.9	5
322	Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 266-273.	1.2	1
323	Mepolizumab as Anti-interleukin-5 Therapy for Chronic Rhinosinusitis with Nasal Polyposis. <i>US Respiratory &amp; Pulmonary Diseases</i> , 2021, 6, 42.	0.2	0
324	Biological Treatments and Target Therapies for Pediatric Respiratory Medicine: Not Only Asthma. <i>Frontiers in Pediatrics</i> , 2022, 10, 837667.	0.9	3
325	Type I conventional dendritic cells relate to disease severity in virus-induced asthma exacerbations. <i>Clinical and Experimental Allergy</i> , 2022, 52, 550-560.	1.4	3
326	The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1413-1423.	1.5	41
327	Mepolizumab response in severe chronic rhinosinusitis with nasal polyps is dissociated from blood eosinophil levels. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1817.	1.5	2
328	Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. <i>Chest</i> , 2022, 162, 297-308.	0.4	2
329	Eosinophilic airway diseases: basic science, clinical manifestations and future challenges. <i>European Clinical Respiratory Journal</i> , 2022, 9, 2040707.	0.7	5
330	Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 169-180.	0.5	28
331	Novel Potential Treatable Traits in Asthma: Where is the research taking us?. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
332	Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1183-1194.	1.4	5
333	Use of Biologic Therapies in the Treatment of Asthma – A Comparative Real World Data Analysis on Healthcare Resource Utilization and Costs Before and After Therapy Initiation. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 407-418.	1.5	5
334	Pharmacological approaches to target type 2 cytokines in asthma. , 2022, 237, 108167.		8
335	Typ-2-Inflammation: Stellenwert verschiedener Biologika in der Praxis. , 0, , .		0
337	Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective. <i>Children</i> , 2021, 8, 1165.	0.6	10
338	2021 Brazilian Thoracic Association recommendations for the management of severe asthma. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210273.	0.4	9
339	Biologics in severe asthma – a molecular perspective. <i>Alergologia</i> , 2022, 1, 33.	0.1	1
340	Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease. <i>Internal Medicine</i> , 2023, 62, 21-25.	0.3	4
341	Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts. <i>Frontiers in Pharmacology</i> , 2022, 13, 836635.	1.6	4
345	Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2367-2374.e3.	2.0	10
346	Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker–high and –low severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2974-2986.	2.7	11
347	Sub–stratification of type–2 high airway disease for therapeutic decision–making: A –bomb– (blood) Tj ETQg1 1 0.784314 rgB 1.3 18		
348	Mendelian randomisation of eosinophils and other cell types in relation to lung function and disease. <i>Thorax</i> , 2023, 78, 496-503.	2.7	6
349	The new era of add-on asthma treatments: where do we stand?. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, .	0.9	12
350	New perspectives of biological therapy for severe asthma in adults and adolescents. <i>Swiss Medical Weekly</i> , 2022, 152, w30176.	0.8	3
351	Serum interleukin 38 (IL-38) as a new potential biomarker of pediatric asthma. <i>Egyptian Journal of Bronchology</i> , 2022, 16, .	0.3	0
352	Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 855-870.	1.4	2
353	EoE behaves as a unique Th2 disease: a narrative review. <i>Translational Gastroenterology and Hepatology</i> , 0, 8, 11-11.	1.5	3

#	ARTICLE	IF	CITATIONS
354	Sputum Metabolomic Profiling Reveals Metabolic Pathways and Signatures Associated With Inflammatory Phenotypes in Patients With Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 393.	1.1	7
355	Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1097-1105.e12.	1.5	23
356	Anti-IL-5 therapies for asthma. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	11
357	An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma. <i>European Respiratory Journal</i> , 2022, 60, 2103205.	3.1	5
358	Stepped treatment algorithm using budesonide-formoterol for chronic respiratory diseases: A single arm interventional study. <i>PLoS ONE</i> , 2022, 17, e0271178.	1.1	0
359	We need to understand why viral infections lead to acute asthma. <i>European Respiratory Journal</i> , 2022, 60, 2200194.	3.1	0
360	Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. <i>Cell Discovery</i> , 2022, 8, .	3.1	9
361	A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab. <i>Turkish Thoracic Journal</i> , 2022, 23, 348-354.	0.2	5
362	Current and emerging biologic therapies targeting eosinophilic disorders. <i>World Allergy Organization Journal</i> , 2022, 15, 100676.	1.6	17
363	Mepolizumab prefilled syringe for the treatment of severe eosinophilic asthma: focus on the pediatric population. <i>Expert Review of Respiratory Medicine</i> , 0, , 1-9.	1.0	1
364	Precision Medicine in Asthma Therapy. <i>Handbook of Experimental Pharmacology</i> , 2022, , 85-106.	0.9	2
365	Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2375-2377.	2.0	1
367	Overview of recent advancements in asthma management. <i>Internal Medicine Journal</i> , 2022, 52, 1478-1487.	0.5	0
368	Rethinking blood eosinophil counts: Epidemiology, associated chronic diseases, and increased risks of cardiovascular disease. , 2022, 1, 233-240.		8
369	A pragmatic randomised controlled trial of tailored pulmonary rehabilitation in participants with difficult-to-control asthma and elevated body mass index. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	2
370	Recent insights in the role of biomarkers in severe asthma management. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
371	Evaluation of real-life data in patients with severe eosinophilic asthma treated with mepolizumab. <i>Journal of Medicine and Palliative Care</i> , 2022, 3, 275-279.	0.0	0
372	Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development ( ) Tj ETQq1 1 0.784314 rgBT /Overlook Therapeutics, 0, , .	2.3	5

#	ARTICLE	IF	CITATIONS
373	Phenotyping, Precision Medicine, and Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 739-751.	0.8	1
374	Asthma Exacerbations During the Pandemic: Time to Rethink Clinical Markers. , 2022, , .		0
375	Eosinophilic and noneosinophilic asthma: Beyond severe asthma. , 2023, , 31-46.		0
376	Well Known and Unknown Asthma Phenotype: Allergic Asthma. <i>European Medical Journal Allergy &amp; Immunology</i> , 0, , 76-87.	0.0	0
377	Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach. <i>Frontiers in Allergy</i> , 0, 3, .	1.2	2
378	Fractional Exhaled Nitric Oxide (FeNO) in Patients with Stable Chronic Obstructive Pulmonary Disease: Short-Term Variability and Potential Clinical Implications. <i>Journal of Personalized Medicine</i> , 2022, 12, 1906.	1.1	1
379	Consequences of severe asthma exacerbations. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2023, 23, 44-50.	1.1	3
380	Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. <i>Allergology International</i> , 2023, 72, 11-23.	1.4	25
381	Therapeutic Potential of Controlled Delivery Systems in Asthma: Preclinical Development of Flavonoid-Based Treatments. <i>Pharmaceutics</i> , 2023, 15, 1.	2.0	4
382	Characteristics of Induced-Sputum Inflammatory Phenotypes in Adults with Asthma: Predictors of Bronchial Eosinophilia. <i>Journal of Asthma and Allergy</i> , 0, Volume 16, 95-103.	1.5	2
383	Pediatric obesity and severe asthma: Targeting pathways driving inflammation. <i>Pharmacological Research</i> , 2023, 188, 106658.	3.1	7
384	Asthma in Childhood: Current Perspectives on Diagnosis and Treatment. <i>European Medical Journal Respiratory</i> , 0, , 90-99.	1.0	0
385	The Lancet Asthma Commission: Towards the Abolition of Asthma?. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 10-15.	3.0	6
386	Blood eosinophil count variability in chronic obstructive pulmonary disease and severe asthma. <i>Allergology International</i> , 2023, 72, 402-410.	1.4	6
387	Eosinophilia attention, diagnosis, treatment, and awareness in physicians: a cross-sectional survey. <i>Therapeutic Advances in Chronic Disease</i> , 2023, 14, 204062232211469.	1.1	3
389	Biologics in the treatment of asthma in children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 581-589.	1.5	12
390	Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
391	Biological drugs in the treatment of atopic diseases in pediatric patients. , 2023, , 15-35.		0

#	ARTICLE	IF	CITATIONS
392	Cost-Effectiveness of Mepolizumab Add-On in the Treatment of Severe Eosinophilic Asthma in Chile. Value in Health Regional Issues, 2023, 35, 69-77.	0.5	1
394	Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5. Chest, 2023, 163, 1368-1379.	0.4	15
395	Organization of biological therapy for patients with severe eosinophilic bronchial asthma in the Krasnoyarsk region. Pulmonologiya, 2023, 33, 119-127.	0.2	0
396	Mepolizumab for the treatment of chronic rhinosinusitis with nasal polyps in adults. Expert Review of Respiratory Medicine, 2023, 17, 109-118.	1.0	0
397	Baseline Characteristics of Patients Enrolled in Clinical Trials of Biologics for Severe Asthma as Potential Predictors of Outcomes. Journal of Clinical Medicine, 2023, 12, 1546.	1.0	3
398	Clinical profiles of patients referred for biological therapy and major limitations in the qualification paths in a specialist asthma centre. Postepy Dermatologii I Alergologii, 2023, 40, 93-101.	0.4	0
399	Comparative effectiveness of <scp>anti-IL5</scp> and <scp>anti-IgE</scp> biologic classes in patients with severe asthma eligible for both. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 1934-1948.	2.7	9
400	Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2023, 208, 13-24.	2.5	23
406	Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. Advances in Pharmacology, 2023, , 31-54.	1.2	0
407	Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review. Advances in Therapy, 2023, 40, 2944-2964.	1.3	5
410	Clinical Trial Design Innovations for Precision Medicine in Asthma. Advances in Experimental Medicine and Biology, 2023, , 395-412.	0.8	1